/SGRY
SGRY Stock - Surgery Partners, Inc.
Healthcare|Medical - Care FacilitiesNASDAQ
$15.70-0.82%
$0.13 (-0.82%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.4
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.43
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+25.3%upside
Target: $19.67
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SGRY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$15.54 – $15.86
TARGET (TP)$19.67
STOP LOSS$14.44
RISK/REWARD1:3.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.93
52W High$26.16
52W Low$14.94
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.11B | $2.74B | $2.54B | $2.23B | $1.86B |
| Gross Profit | $745.60M | $647.50M | $574.90M | $491.40M | $379.80M |
| Gross Margin | 23.9% | 23.6% | 22.6% | 22.1% | 20.4% |
| Operating Income | $348.80M | $328.00M | $345.20M | $302.20M | $183.00M |
| Net Income | $-168,100,000 | $-11,900,000 | $-54,600,000 | $-70,900,000 | $-116,100,000 |
| Net Margin | -5.4% | -0.4% | -2.2% | -3.2% | -6.2% |
| EPS | $-1.33 | $-0.09 | $-0.59 | $-1.12 | $-3.19 |
Company Overview
Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of multi-specialty physician practices, urgent care facilities, and anesthesia services. As of December 31, 2021, it owned or operated a portfolio of 126 surgical facilities, including 108 ambulatory surgical centers and 18 surgical hospitals in 31 states. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
73%
Hold / Neutral
3
27%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
8 Bullish3 Neutral/Bearish
Price Targets
$37
Average Target
↑ 135.7% Upside
Now
$27
Low
$37
Average
$48
High
Based on 12 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 18th 2025 | JP Morgan | Resumed | Neutral | $27 |
| July 28th 2025 | BofA Securities | Resumed | Buy | $28 |
| December 16th 2024 | BofA Securities | Initiation | Buy | $30 |
| October 14th 2024 | UBS | Initiation | Buy | $38 |
| October 11th 2024 | KeyBanc Capital Markets | Initiation | Sector Weight | - |
| June 28th 2024 | Macquarie | Initiation | Outperform | $31 |
| March 6th 2024 | Barclays | Initiation | Equal Weight | $35 |
| November 14th 2023 | TD Cowen | Upgrade | Outperform | $35← $39 |
| June 2nd 2023 | BofA Securities | Upgrade | Buy | $45← $42 |
| May 12th 2023 | Mizuho | Initiation | Buy | $48 |
| April 21st 2023 | Cantor Fitzgerald | Initiation | Overweight | $43 |
| November 23rd 2022 | RBC Capital Mkts | Reiterated | Outperform | $48← $58 |
| June 15th 2022 | BofA Securities | Downgrade | Neutral | $36← $55 |
Earnings History & Surprises
SGRYBeat Rate
44%
Last 18 quarters
Avg Surprise
+88.8%
EPS vs Estimate
Beats / Misses
8/9
1 met exactly
Latest EPS
$0.13
Q4 2025
EPS Surprise History
Q1 24
+18.9%
$0.44vs$0.37
Q2 24
+42.9%
$0.10vs$0.07
Q3 24
0.0%
$0.21vs$0.21
Q4 24
-24.0%
$0.19vs$0.25
Q1 25
+15.8%
$0.44vs$0.38
Q2 25
-50.0%
$0.04vs$0.08
Q3 25
+6.3%
$0.17vs$0.16
Q4 25
-31.6%
$0.13vs$0.19
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 2, 2026 | $0.31 | — | — | — |
Q4 2025 | Nov 10, 2025 | $0.19 | $0.13 | -31.6% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $0.16 | $0.17 | +6.3% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $0.08 | $0.04 | -50.0% | ✗ MISS |
Q1 2025 | Mar 3, 2025 | $0.38 | $0.44 | +15.8% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $0.25 | $0.19 | -24.0% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $0.21 | $0.21 | 0.0% | = MET |
Q2 2024 | May 7, 2024 | $0.07 | $0.10 | +42.9% | ✓ BEAT |
Q1 2024 | Feb 26, 2024 | $0.37 | $0.44 | +18.9% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $0.14 | $0.19 | +35.7% | ✓ BEAT |
Q3 2023 | Aug 1, 2023 | $0.07 | $0.28 | +300.0% | ✓ BEAT |
Q2 2023 | May 1, 2023 | $0.00 | $0.08 | +1951.3% | ✓ BEAT |
Q1 2023 | Mar 1, 2023 | $0.19 | $0.27 | +42.1% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.01 | $-0.02 | -143.9% | ✗ MISS |
Q3 2022 | Aug 2, 2022 | $-0.01 | $-0.03 | -344.4% | ✗ MISS |
Q2 2022 | May 3, 2022 | $-0.05 | $-0.09 | -80.0% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $0.26 | $0.23 | -11.5% | ✗ MISS |
Q4 2021 | Nov 2, 2021 | $-0.03 | $-0.05 | -52.1% | ✗ MISS |
Q3 2021 | Aug 4, 2021 | $-0.22 | $-0.39 | -76.5% | ✗ MISS |
Latest News
Mizuho Maintains Outperform on Surgery Partners, Lowers Price Target to $19
➖ NeutralBenzinga•Dec 18, 2025, 01:16 PM
Reported Earlier, Surgery Partners Prices $425.0M Add-On Offering Of 7.250% Senior Unsecured Notes Due 2032
➖ NeutralBenzinga•Dec 12, 2025, 08:25 AM
Surgery Partners Plans $425M Add-On Offering Of 7.25% Senior Unsecured Notes Due 2032
➖ NeutralBenzinga•Dec 11, 2025, 01:37 PM
Surgery Partners Teams Up With Baylor Scott & White Health To Co-Own And Manage The Physicians Centre Hospital In Bryan, Texas
📈 PositiveBenzinga•Dec 8, 2025, 05:02 PM
JP Morgan Maintains Neutral on Surgery Partners, Lowers Price Target to $20
➖ NeutralBenzinga•Nov 24, 2025, 03:28 PM
Barclays Maintains Equal-Weight on Surgery Partners, Lowers Price Target to $18
➖ NeutralBenzinga•Nov 21, 2025, 05:41 PM•Also:
Mizuho Maintains Outperform on Surgery Partners, Lowers Price Target to $22
➖ NeutralBenzinga•Nov 17, 2025, 05:40 PM
UBS Maintains Buy on Surgery Partners, Lowers Price Target to $29
📈 PositiveBenzinga•Nov 13, 2025, 03:23 PM
RBC Capital Maintains Outperform on Surgery Partners, Lowers Price Target to $31
➖ NeutralBenzinga•Nov 11, 2025, 03:28 PM
Benchmark Maintains Buy on Surgery Partners, Lowers Price Target to $30
📈 PositiveBenzinga•Nov 11, 2025, 01:37 PM
Surgery Partners shares are trading lower after the company reported mixed Q3 financial results and cut its FY25 sales guidance below estimates.
📉 NegativeBenzinga•Nov 10, 2025, 02:04 PM
Surgery Partners Lowers FY2025 Sales Guidance from $3.300B-$3.450B to $3.275B-$3.300B vs $3.352B Est
📉 NegativeBenzinga•Nov 10, 2025, 12:31 PM
Surgery Partners Q3 Adj. EPS $0.13 Misses $0.17 Estimate, Sales $821.500M Beat $821.025M Estimate
➖ NeutralBenzinga•Nov 10, 2025, 12:30 PM
Cantor Fitzgerald Reiterates Overweight on Surgery Partners, Maintains $36 Price Target
📈 PositiveBenzinga•Oct 7, 2025, 01:15 PM
JP Morgan Assumes Surgery Partners at Neutral, Announces Price Target of $27
➖ NeutralBenzinga•Sep 18, 2025, 11:04 AM•Also:
Surgery Partners rejects Bain Capital's takeover proposal
📉 NegativeSeeking Alpha•Jun 17, 2025, 01:02 PM
Surgery Partners gains amid report of AMSURG sale process
📈 PositiveSeeking Alpha•May 16, 2025, 07:10 PM
Frequently Asked Questions about SGRY
What is SGRY's current stock price?
Surgery Partners, Inc. (SGRY) is currently trading at $15.70 per share. The stock has moved -0.82% today.
What is the analyst price target for SGRY?
The average analyst price target for SGRY is $19.67, based on 1 analyst.
What sector is Surgery Partners, Inc. in?
Surgery Partners, Inc. operates in the Healthcare sector, specifically within the Medical - Care Facilities industry. The company is traded on the NASDAQ exchange.
What is SGRY's market cap?
Surgery Partners, Inc. has a market capitalization of $2.03 billion, making it a mid-cap company.
Does SGRY pay dividends?
No, Surgery Partners, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARDT
Ardent Health Partners, LLC
$8.81
Mkt Cap: $1.3B
ATEC
Alphatec Holdings, Inc.
$20.01
Mkt Cap: $3.0B
BKD
Brookdale Senior Living Inc.
$10.79
Mkt Cap: $2.6B
CDTX
Cidara Therapeutics, Inc.
$220.80
Mkt Cap: $5.6B
HTFL
Heartflow, Inc. Common Stock
$30.51
Mkt Cap: $2.6B
IDYA
IDEAYA Biosciences, Inc.
$33.55
Mkt Cap: $2.9B
LEGN
Legend Biotech Corporation
$21.92
Mkt Cap: $2.0B
LIVN
LivaNova PLC
$62.82
Mkt Cap: $3.4B
SRRK
Scholar Rock Holding Corporation
$43.90
Mkt Cap: $4.5B
ZLAB
Zai Lab Limited
$18.04
Mkt Cap: $2.0B
Explore stocks similar to SGRY for comparison